Twenty-six patients (50%)had PT including 14 (53.8%)CML, nine (34.6%) JAK2 V617F mutated ET, one (3.9 %) CALR mutated ET, one (3.9%) JAK2V617F mutated PMF, and one (3.9%) JAK2V617F mutated PV. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.